Drug

InnoCare's Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China's First BTD‑Designated BCL2 Inhibitor
Clinical trial approval / initiationHKG: 9969

InnoCare’s Mesutoclax Wins CDE Approval for Registrational Phase III Trial With Orelabrutinib in Relapsed/Refractory MZL – Fifth Registrational Study for China’s First BTD‑Designated BCL2 Inhibitor

InnoCare Pharma (HKG: 9969; SHA: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced that the Center for Drug Evaluation (CDE) of China's National…

Laekna's LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

Laekna’s LAE102 Delivers Promising Weight Loss With Lean Mass Gains in Completed 24‑Week Low‑Dose Monotherapy Cohorts – Selective ActRIIA Antibody Well Tolerated, High‑Dose Cohort Fully Enrolled

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

CARsgen Doses First Patient in Registrational Phase I Trial of CT0596 – Allogeneic BCMA CAR‑T Built on THANK‑u Plus® Platform Advances Toward Relapsed/Refractory Multiple Myeloma

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
Bio-Thera SolutionsBiosimilars

Bio-Thera’s Stelara Biosimilar Usymro Wins UK Approval – Expands European Market Access via Gedeon Richter

Kexing BiopharmSHA: 688136

Kexing Biopharma’s GB19 Wins NMPA Approval for Cutaneous Lupus – BDCA2‑Targeted Therapy Expands Autoimmune Pipeline

J&J's Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases
J&JJohnson & Johnson

J&J’s Nipocalimab Wins FDA Fast Track for Lupus – FcRn Blocker Targets Autoantibody Diseases

Asieris Pharma's Cevira Wins NMPA Approval – World's First Non‑Surgical Photodynamic Therapy for Cervical Lesions
Asieris PharmaceuticalsProduct approvals

Asieris Pharma’s Cevira Wins NMPA Approval – World’s First Non‑Surgical Photodynamic Therapy for Cervical Lesions

Show More